Premium
Misidentification of recombinant hepatitis C virus leading to treatment failure with direct acting antivirals
Author(s) -
Mourez Thomas,
Decroos Amandine,
Goria Odile,
Montialoux Hélène,
De Oliveira Fabienne,
Larrat Sylvie,
Plantier JeanChristophe,
Riachi Ghassan
Publication year - 2018
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.25035
Subject(s) - genotyping , virology , genotype , genome , hepatitis c virus , recombinant dna , biology , breakpoint , virus , computational biology , genetics , gene , chromosomal translocation
The use of new Direct Acting Antivirals, specific of HCV, has greatly improved the HCV treatment. Most of the DAA are specific of HCV genotypes. Genotyping methods may target different regions of the HCV genome, though only the whole genome sequencing could confirm the correct genotype. The present study describes the virological investigation of a treatment failure due to the false identification of an unusual 2k/1b recombinant HCV form. It describes the sequencing methods, and the similarity analysis of the sequences to different genotype query sequences, to identify the recombination breakpoint.